researc-dev1

Research & Development

Sanofi Pasteur MSD is proud to potentially be able to draw from two world leading pipelines for its vaccine development and delivery.

  • Sanofi Pasteur MSD Pipeline

    Phase III Registration New Vaccines

    Quadrivalent Influenza Vaccine

    Pediatric Hexavalent Vaccine

    9 valent HPV vaccine (V503)

    Hexyon (2014)

    Zostavax (2014)

    ProQuad

  • Sanofi Pasteur R&D Pipeline – 12 vaccines in development1

    Phase I Phase II Phase III Registration

    Streptococcus pneumoniae

    Meningitis & pneumonia vaccine

    Herpes Simplex Virus Type 2

    HSV-2 vaccine

    Meningitis ACYW conj

    2nd generation meningococcal conjugate infant vaccine

    Rage VRVg

    Purified vero rabies vaccine

    Rotavirus

    Live attenuated tetravalent Rotavirus oral vaccine

    Tuberculosis

    Recombinant subunit vaccine

    Dengue

    Mid to severe dengue fever

    Vaxigrip® QIV IM

    Quadrivalent inactivated influenza vaccine

    DTP-HepB-Polio-Hib (PR5I)

    Pediatric hexavalent vaccine

    Clostridium difficile

    Toxoid vaccine

    Quadracel®

    Diphtheria, tetanus pertussis & polio vaccine; 4-y of age

    Fluzone® QIV ID

    Quadrivalent inactivated influenza vaccine Intradermal

    1 source : Sanofi Pasteur Pipeline, July 31 2014, phase I to registration

  • Merck R&D Pipeline1

    Phase II Phase III Under Review

    Pneumoconjugate Vaccine,

    V114

    Pediatric Hexavalent Combination Vaccine,

    V419

    Herpes Zoster Inactivated VZV Vaccine,

    V212

    HPV-Related Cancers

    HPV Vaccine (9 Valent)
    V503 (US)

     

    1 : Source : Merck Pipeline as of April 30, 2014

  • Sanofi Pasteur MSD pipelinespmsdpipeline
  • Sanofi Pasteur R&D Portfoliosanofipasteurpipeline
  • Merck R&D Portfoliomerckpipeline